Piper Jaffray & Co. upgrades Regeneron Pharmaceuticals (Nasdaq: REGN) from Neutral to Buy. Price target $19.

Piper analyst ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE